| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Artiva Biotherapeutics, Inc. (ARTV) has 13 insiders with recent SEC Form 4 filings, including 8 buys and 4 sells. ARTV is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.21M | $13.18M | - | |
| COO | 232.9K | $2.54M | - | |
| VP | 106.8K | $1.16M | - | |
| CFO | 99.4K | $1.08M | - | |
| Dir | 27.5K | $299.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 15, 2025 | Aslan Fred | President And CEO | Sell | 3,187 | $6.00 | $19,122.00 | -0.3% | -1.9% | - | |
| Nov 17, 2025 | Aslan Fred | President And CEO | Sell | 6,375 | $3.38 | $21,522.00 | -1.8% | +17.1% | - | |
| Oct 17, 2025 | Aslan Fred | President And CEO | Sell | 25,500 | $6.00 | $153,000.00 | -6.7% | -25.8% | - | |
| Aug 15, 2025 | Aslan Fred | President And CEO | Sell | 25,500 | $2.73 | $69,579.30 | -6.2% | +23.3% | - | |
| Jul 22, 2024 | Ra Capital Management, L.P.52 | Director, 10% Owner | Buy | 8,333,333 | $12.00 | $99,999,996.00 | +702.0% | -11.0% | -78.1% | |
| Jul 22, 2024 | Gc Corp. | 10% Owner | Buy | 2,083,332 | $12.00 | $24,999,984.00 | +83.9% | -11.0% | -78.1% | |
| Jul 22, 2024 | Huh Yong-Jun | Director | Buy | 2,083,332 | $12.00 | $24,999,984.00 | +83.9% | -11.0% | -78.1% | |
| Jul 22, 2024 | 5am Partners Vi, LLC | 10% Owner | Buy | 833,333 | $12.00 | $9,999,996.00 | +239.0% | -11.0% | -78.1% | |
| Jul 22, 2024 | Venbio Global Strategic Fund Iii, L.P. | - | Buy | 416,666 | $12.00 | $4,999,992.00 | +27.4% | -11.0% | -78.1% |